Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Ray KK, et al. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Lancet Diabetes Endocrinol. 2019. PMID: 31272931 Free article. Clinical Trial.
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG; ODYSSEY OUTCOMES Investigators. Goodman SG, et al. Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):342-352. doi: 10.1093/ehjcvp/pvae025. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38658193 Free PMC article. Review.
Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure.
Ostrominski JW, Aggarwal R, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD, Vaduganathan M. Ostrominski JW, et al. Among authors: aggarwal r. J Card Fail. 2024 Sep;30(9):1170-1174. doi: 10.1016/j.cardfail.2024.04.015. Epub 2024 May 11. J Card Fail. 2024. PMID: 38740173 Free article. Clinical Trial. No abstract available.
Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failure.
Talha KM, Butler J, Greene SJ, Aggarwal R, Anker SD, Claggett BL, Docherty KF, Solomon SD, McMurray JJV, Januzzi JL Jr, Vaduganathan M, Fonarow GC. Talha KM, et al. Among authors: aggarwal r. Eur J Heart Fail. 2023 Jul;25(7):999-1009. doi: 10.1002/ejhf.2864. Epub 2023 Apr 24. Eur J Heart Fail. 2023. PMID: 37062865 Free article.
An automated method of streamlining waiting list by clinical risk fast-tracking for patients awaiting TAVR: SWIFT TAVR algorithm.
Khan S, Demir O, Mehmood M, Nabi I, Kharoud D, Crawford I, Smith S, Fawaz S, Sajjad U, Xue Q, Singh A, Karamasis GV, Keeble T, Davies J, Kabir A, Aggarwal R, Jagathesan R, Cook C. Khan S, et al. Among authors: aggarwal r. Int J Cardiol. 2025 Jan 4:132952. doi: 10.1016/j.ijcard.2024.132952. Online ahead of print. Int J Cardiol. 2025. PMID: 39761831
Comparison of Measured Glomerular Filtration Rate Versus Estimated Glomerular Filtration Rate in Indian Cirrhotic Patients: Report of a Pilot Study.
Divyaveer S, Kashyap M, Kekan K, Yadav AK, Kaur J, Premkumar M, Gandotra A, Prajapati K, De A, Duseja AK, Verma N, Aggarwal R, Venkatasubramanian V, Tiwari V, Bagur V, Patil AN, Safiq N, Kohli HS. Divyaveer S, et al. Among authors: aggarwal r. J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102464. doi: 10.1016/j.jceh.2024.102464. Epub 2024 Nov 22. J Clin Exp Hepatol. 2025. PMID: 39760116
2,229 results